{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:35:28Z","timestamp":1793068528626,"version":"4.5.0"},"reference-count":47,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Most Prostate Specific Membrane Antigens (PSMAs) targeting small molecules accumulate in the salivary glands (SGs), raising concerns about SG toxicity, especially after repeated therapies or therapy with 225Ac-labeled ligands. SG toxicity is assessed clinically by the severity of patient-reported xerostomia, but this parameter can be challenging to objectively quantify. Therefore, we explored the feasibility of using SG volume as a biomarker for toxicity. In 21 patients with late-stage metastatic resistant prostate cancer (mCRPC), the PSMA volume and ligand uptake of SG were analyzed retrospectively before and after two cycles of 177Lu-PSMA (LuPSMA; cohort A) and before and after one cycle of 225Ac-PSMA-617 (AcPSMA, cohort B). Mean Volume-SG in cohort A was 59 \u00b1 13 vs. 54 \u00b1 16 mL (\u221210%, p = 0.4), and in cohort B, it was 50 \u00b1 13 vs. 40 \u00b1 11 mL (\u221220%, p = 0.007), respectively. A statistically significant decrease in the activity concentration in the SG was only observed in group B (SUVmean: 9.2 \u00b1 2.8 vs. 5.3 \u00b1 1.8, p &lt; 0.0001; vs. A: SUVmean: 11.2 \u00b1 3.3 vs. 11.1 \u00b1 3.5, p = 0.8). SG volume and PSMA-ligand uptake are promising markers to monitor the SG toxicity after a PSMA RLT.<\/jats:p>","DOI":"10.3390\/ijms242316845","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T06:45:35Z","timestamp":1701153935000},"page":"16845","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative Analysis of Morphological and Functional Effects of 225Ac- and 177Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands"],"prefix":"10.3390","volume":"24","author":[{"given":"Benedikt","family":"Feuerecker","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Technical University of Munich, 81675 M\u00fcnchen, Germany"},{"name":"Deutsches Konsortium f\u00fcr Translationale Krebsforschung (DKTK), Partnersite M\u00fcnchen, 69124 Heidelberg, Germany"},{"name":"Department of Radiology, University Hospital, LMU Munich, 81377 M\u00fcnchen, Germany"},{"name":"Department of Radiology, School of Medicine, Technical University of Munich, 81675 M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Langbein","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Technical University of Munich, 81675 M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4770-3307","authenticated-orcid":false,"given":"Robert","family":"Tauber","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, 81675 M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Seidl","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Technical University of Munich, 81675 M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[{"name":"European Commission, Joint Research Centre (JRC), 76344 Karlsruhe, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E.","family":"Gschwendt","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, 81675 M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Technical University of Munich, 81675 M\u00fcnchen, Germany"},{"name":"Deutsches Konsortium f\u00fcr Translationale Krebsforschung (DKTK), Partnersite M\u00fcnchen, 69124 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2381-1212","authenticated-orcid":false,"given":"Calogero","family":"D\u2019Alessandria","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Technical University of Munich, 81675 M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[{"name":"European Commission, Joint Research Centre (JRC), 76344 Karlsruhe, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Technical University of Munich, 81675 M\u00fcnchen, Germany"},{"name":"Deutsches Konsortium f\u00fcr Translationale Krebsforschung (DKTK), Partnersite M\u00fcnchen, 69124 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-Targeted alpha-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.120.251017","article-title":"First Clinical Results for PSMA-Targeted alpha-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients","volume":"62","author":"Zacherl","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1748-717X-6-125","article-title":"Parotid gland-recovery after radiotherapy in the head and neck region--36 months follow-up of a prospective clinical study","volume":"6","author":"Hey","year":"2011","journal-title":"Radiat. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2009.07.1708","article-title":"Parotid gland function after radiotherapy: The combined michigan and utrecht experience","volume":"78","author":"Dijkema","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/MNM.0000000000000132","article-title":"Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma","volume":"35","author":"Fallahi","year":"2014","journal-title":"Nucl. Med. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"20210718","DOI":"10.1259\/bjr.20210718","article-title":"Mathematical evaluation of post-radiotherapy salivary gland function using salivary gland scintigraphy","volume":"95","author":"Itonaga","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_11","first-page":"755","article-title":"Sialadenitis following I-131 therapy for thyroid carcinoma: Concise communication","volume":"25","author":"Allweiss","year":"1984","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jamaoncol.2018.4951","article-title":"Assessment of Risk of Xerostomia After Whole-Brain Radiation Therapy and Association With Parotid Dose","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_13","first-page":"ZC60","article-title":"Assessment of Salivary Gland Function Using Salivary Scintigraphy in Pre and Post Radioactive Iodine Therapy in Diagnosed Thyroid Carcinoma Patients","volume":"10","author":"Badam","year":"2016","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00006231-199608000-00006","article-title":"Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine","volume":"17","author":"Bohuslavizki","year":"1996","journal-title":"Nucl. Med. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00006231-199802000-00013","article-title":"Salivary gland scintigraphy after radioiodine therapy","volume":"19","author":"Malpani","year":"1998","journal-title":"Nucl. Med. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/lary.28342","article-title":"Does Salivary Function Decrease in Proportion to Radioiodine Dose?","volume":"130","author":"Kim","year":"2020","journal-title":"Laryngoscope"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Langbein, T., Kulkarni, H.R., Schuchardt, C., Mueller, D., Volk, G.F., and Baum, R.P. (2022). Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation. Diagnostics, 12.","DOI":"10.3390\/diagnostics12081926"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","article-title":"Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients","volume":"10","author":"Yadav","year":"2020","journal-title":"Theranostics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.ijrobp.2004.12.051","article-title":"On the mechanism of salivary gland radiosensitivity","volume":"62","author":"Konings","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s003300000728","article-title":"MRI appearance of radiation-induced changes of normal cervical tissues","volume":"11","author":"Nomayr","year":"2001","journal-title":"Eur. Radiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ijrobp.2003.12.024","article-title":"Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT\/linear accelerator system","volume":"59","author":"Barker","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1259\/bjr\/55873561","article-title":"Evaluation of radiation-induced changes to parotid glands following conventional radiotherapy in patients with nasopharygneal carcinoma","volume":"84","author":"Wu","year":"2011","journal-title":"Br. J. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"531660","DOI":"10.3389\/fonc.2020.531660","article-title":"Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)","volume":"10","author":"Belli","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","article-title":"Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer","volume":"42","author":"Kabasakal","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2967\/jnumed.121.262671","article-title":"Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"63","author":"Feuerecker","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2967\/jnumed.122.264293","article-title":"177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer","volume":"64","author":"Derlin","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2967\/jnumed.118.207993","article-title":"PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?","volume":"59","author":"Taieb","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/00220345920710070301","article-title":"Clinical criteria for the diagnosis of salivary gland hypofunction","volume":"71","author":"Navazesh","year":"1992","journal-title":"J. Dent. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"55094","DOI":"10.18632\/oncotarget.19049","article-title":"Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer","volume":"8","author":"Gaertner","year":"2017","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2967\/jnumed.121.261906","article-title":"Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality?","volume":"63","author":"Gafita","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s11307-019-01375-w","article-title":"Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake","volume":"22","author":"Werner","year":"2020","journal-title":"Mol. Imaging Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2967\/jnumed.118.222307","article-title":"First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands","volume":"60","author":"Rupp","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Tonnesmann, R., Meyer, P.T., Eder, M., and Baranski, A.C. (2019). [177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography. Pharmaceuticals, 12.","DOI":"10.3390\/ph12010018"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3413\/Nukmed-0937-17-10","article-title":"Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy","volume":"57","author":"Filss","year":"2018","journal-title":"Nuklearmedizin"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12149-021-01593-9","article-title":"Predictive factors of tumor sink effect: Insights from 177Lu-Prostate-specific membrane antigen therapy","volume":"35","author":"Tuncel","year":"2021","journal-title":"Ann. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s00259-017-3665-9","article-title":"Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095","volume":"44","author":"Haberkorn","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","article-title":"Radiation dosimetry and first therapy results with a 124I\/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy","volume":"41","author":"Zechmann","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"101445","DOI":"10.1016\/j.tranon.2022.101445","article-title":"Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management","volume":"21","author":"Mahajan","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.3390\/curroncol28050315","article-title":"Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"28","author":"Wollenweber","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","article-title":"Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer","volume":"41","author":"Rahbar","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/RLU.0000000000002561","article-title":"First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands","volume":"44","author":"Braat","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","article-title":"qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET\/CT","volume":"60","author":"Gafita","year":"2019","journal-title":"J. Nucl. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16845\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:32:06Z","timestamp":1760131926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":47,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ijms242316845"],"URL":"https:\/\/doi.org\/10.3390\/ijms242316845","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]}}}